Patents Examined by Rebecca Cook
  • Patent number: 6855712
    Abstract: The use of a protecting agent, for example a folate derivative such as folic acid or leucovorin, in combination with a non-competitive folic acid analogue, for example benzoquinazoline derivatives, for use in reducing the side effects associated with the administration of such non-competitive folic acid analogues, and pharmaceutical formulations comprising such combinations are disclosed.
    Type: Grant
    Filed: May 7, 2003
    Date of Patent: February 15, 2005
    Assignee: SmithKline Beecham Corporation
    Inventors: Gary Keith Smith, David Stanley Duch, Robert Ferone, Arthur Koch
  • Patent number: 6849661
    Abstract: The present invention is directed to methods of treating, preventing, and/or managing abnormal increases in gastrointestinal motility, and intestinal conditions that cause the same. Such conditions include, but are not limited to, irritable bowel syndrome (IBS), infectious diseases of the small and large intestines, and symptoms of any of the foregoing. In particular, the present invention discloses methods of using enriched (R)-verapamil, as well as compositions and formulations containing the same.
    Type: Grant
    Filed: November 15, 2002
    Date of Patent: February 1, 2005
    Assignee: AGI Therapeutics, Ltd.
    Inventors: John Kelly, John Devane, Ted G. Dinan, P.W. Napoleon Keeling
  • Patent number: 6844365
    Abstract: It is disclosed the use of diacerein or a pharmaceutically acceptable derivative thereof for the manufacture of a pharmaceutical composition for the treatment of psoriasis or diseases associated therewith, such as psoriatic arthritis.
    Type: Grant
    Filed: March 2, 2001
    Date of Patent: January 18, 2005
    Assignee: Laboratoire Medidom S.A.
    Inventor: Guido Di Napoli
  • Patent number: 6835740
    Abstract: Methods for the prevention, treatment, or management of apnea, apnea disorders, bulimia, nervosa, irritable bowel syndrome, urinary incontinence, bradycardia, bradyarrhythmia, syncope, other disorders, or symptoms thereof using (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (−) stereoisomer.
    Type: Grant
    Filed: February 15, 2002
    Date of Patent: December 28, 2004
    Assignee: Sepracor Inc.
    Inventors: Paul D. Rubin, Timothy J. Barberich
  • Patent number: 6828320
    Abstract: Substituted heteroaromatic compounds, and in particular substituted quinolines and quinazolines, are protein tyrosine kinase inhibitors. The compounds are described as are methods for their preparation, pharmaceutical compositions including such compounds and their use in medicine, for example in the treatment of cancer and psoriasis.
    Type: Grant
    Filed: January 31, 2002
    Date of Patent: December 7, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: George Stuart Cockerill, Malcolm Clive Carter, Stephen Barry Guntrip, Kathryn Jane Smith
  • Patent number: 6825224
    Abstract: The present invention relates to novel compounds, methods of preparing these compounds, and pharmaceutical compositions comprising these compounds. These compounds are carbamate prodrugs that convert to active inhibitors of the IMPDH enzyme in vivo. The compounds and pharmaceutical compositions of this invention are particularly well suited for activation and subsequent inhibition of the IMPDH enzyme activity. Consequently, these prodrugs may be advantageously used as therapeutic agents for IMPDH mediated processes. This invention also relates to methods for inhibiting the activity of IMPDH using the compounds and compositions of this invention.
    Type: Grant
    Filed: April 17, 2002
    Date of Patent: November 30, 2004
    Assignee: Vertex Pharmaceuticals, Incorporated
    Inventors: Dean P. Stamos, Randy S. Bethiel
  • Patent number: 6803387
    Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl) cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for treating fibromyalgia or neuropathic pain, such as pain associated with diabetes mellitus, shingles, nerve injury and varied peripheral neuropathies.
    Type: Grant
    Filed: March 17, 2000
    Date of Patent: October 12, 2004
    Assignee: Abbott GmbH & Co. KG
    Inventors: Carl M. Mendel, Timothy B. Seaton, Steve P. Weinstein, Edward Chong
  • Patent number: 6803386
    Abstract: The present invention is directed to a pharmaceutical composition containing a cancer-treating effective amount of a class of prostacyclin derivatives, and a pharmaceutically acceptable carrier, and to kits and methods of employing the same for the treatment of cancer.
    Type: Grant
    Filed: January 16, 2002
    Date of Patent: October 12, 2004
    Assignee: United Therapeutics Corporation
    Inventors: Robert Shorr, Martine Rothblatt
  • Patent number: 6800661
    Abstract: Investigation of the activity of extracts of the clam Spisula polynyma has led to antitumour long-chain, straight-chain alkane or alkene compounds which have a 2-amino group and a 3-hydroxy group.
    Type: Grant
    Filed: August 31, 1999
    Date of Patent: October 5, 2004
    Assignee: Board of Trustees of the University of Illinois
    Inventors: Kenneth L. Rinehart, Robert A. Warwick, Jesus Avila, Nancy L. Fregeau Gallagher, Dolores Garcia Gravalos, Glynn T. Faircloth
  • Patent number: 6797722
    Abstract: The present invention discloses a method for treating a subject affected by an autoimmune disease, in particular multiple sclerosis, lupus erythematosus systemicus and reumatoid arthritis, comprising administering to said subject an effective amount of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole. The present invention further discloses a method for inhibiting &ggr;&dgr; T cells in a subject in need thereof, said method comprising administering to said subject an effective amount of the same compound.
    Type: Grant
    Filed: May 3, 2002
    Date of Patent: September 28, 2004
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Luca Battistini, Giovanna Borsellino, Rita De Santis, Paolo Carminati
  • Patent number: 6770304
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
    Type: Grant
    Filed: November 10, 1998
    Date of Patent: August 3, 2004
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Raymond P. Warrell, Jr., Pier Paolo Pandolfi, Janice L. Gabrilove
  • Patent number: 6762174
    Abstract: The present invention relates to peptide-like compounds, e.g. aminocarboxylic acid amide derivatives, and to methods of using same to stimulate cells of the immune system, bone marrow and other organs. The present compounds can be used to enhance vaccination, increase synthesis of and enhance function of blood cell components and enhance anti-neoplastic effects of various agents. The compounds of the invention can be used to produce a variety of further pharmacologic effects.
    Type: Grant
    Filed: February 24, 1999
    Date of Patent: July 13, 2004
    Assignee: Dovetail Technologies, Inc.
    Inventor: Floyd E. Taub
  • Patent number: 6759397
    Abstract: The invention provides for the use of ginsenoside Rh2 in pharmaceutical compositions used in methods of inhibiting the multiplication of cancer cells, and methods of treating cancer in patients, comprising administering to such patients therapeutically and synergistically effective amounts of Rh2 in combination with a chemotherapeutic selected from the group consisting of paclitaxel and mitoxantrone. The cancer cells to be treated may be multidrug resistant. The cancer cells may for example be prostate cancer cells or breast cancer cells.
    Type: Grant
    Filed: May 1, 2001
    Date of Patent: July 6, 2004
    Assignee: The University of British Columbia
    Inventor: William Jia
  • Patent number: 6747036
    Abstract: The present invention provides a novel method for treating leukemia and more particularly acute myelogenous leukemia (AML) in a host comprising administering to the host a therapeutically effective amount of a compound having the formula I: wherein B is cytosine or 5-fluorocytosine and R is selected from the group comprising H, monophosphate, diphosphate, triphosphate, carbonyl substituted with a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, and wherein each Rc is independently selected from the group comprising H, C1-6 alkyl, C2-6 alkynyl, C2-6 alkynyl and an hydroxy protecting group; and wherein said compound is substantially in the form of the (−) enantiomer.
    Type: Grant
    Filed: January 16, 2002
    Date of Patent: June 8, 2004
    Assignee: BioChem Pharma Inc.
    Inventors: Henriette Gourdeau, Francis J. Giles
  • Patent number: 6743822
    Abstract: Hair growth can be reduced using a composition including optically pure L-&agr;-difluoromethylornithine or &agr;-difluoromethylornithine including a preponderance of L-&agr;-difluoromethylornithine.
    Type: Grant
    Filed: July 17, 2002
    Date of Patent: June 1, 2004
    Assignee: The Gillette Company
    Inventors: Peter Styczynski, Gurpreet S. Ahluwalia, Douglas Shander
  • Patent number: 6740659
    Abstract: The invention relates to the use of compounds which inhibit selectively mu opioid receptor activity, or activation, for the treatment of dyskinesia (which, for example, may arise as a side effect of L-DOPA therapy). The compounds used are preferably mu opioid receptor antagonists such as cyprodime.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: May 25, 2004
    Assignee: Motac Neuroscience Limited
    Inventor: Jonathan Brotchie
  • Patent number: 6734178
    Abstract: A method of treatment of a host with a cellular proliferative disease, comprising contacting the host with a cephalotaxine and an antiproliferative agent, each in an amount sufficient to modulate said cellular proliferative disease, is described. In some embodiments, the cephalotaxine comprises homoharringtonine (cephalotaxine, 4-methyl-2-hydroxy-2-(4-hydroxy-4-methyl pentyl) butanediocate ester). Antiproliferative agents of the invention comprise alkylating agents, intercalating agents, metal coordination complexes, pyrimidine nucleosides, purine nucleosides, inhibitors of nucleic acid associated enzymes and proteins, and agents affecting structural proteins and cytoplasmic enzymes.
    Type: Grant
    Filed: March 15, 2001
    Date of Patent: May 11, 2004
    Assignee: ChemGenex Therapeutics, Inc.
    Inventor: Dennis M. Brown
  • Patent number: 6730701
    Abstract: The present invention provides compositions useful for the treatment of inflammation in humans, and related methods of treatment for the same. In one embodiment the composition is: In another embodiment, the composition is: In yet another embodiment, the composition is: Additional alternative embodiments are R or R″ are therapeutic moieties.
    Type: Grant
    Filed: October 29, 2002
    Date of Patent: May 4, 2004
    Assignee: Nobex Corporation
    Inventors: Nnochiri Nkem Ekwuribe, Jennifer A. Riggs-Sauthier
  • Patent number: 6727286
    Abstract: The present invention provides a pharmaceutical composition comprising an aqueous solution of arginine and ibuprofen, wherein the molar ratio of arginine to ibuprofen is less than 1:1, as well as a method of making the same. The present invention also provides a method of treating a condition chosen from pain, inflammation, fever, and/or other conditions alleviated by ibuprofen comprising administering a pharmaceutical composition comprising an aqueous solution of arginine and ibuprofen, wherein the molar ratio of arginine to ibuprofen is less than 1:1.
    Type: Grant
    Filed: November 2, 2001
    Date of Patent: April 27, 2004
    Assignee: Cumberland Pharmaceuticals Inc.
    Inventor: Leo Pavliv
  • Patent number: 6720345
    Abstract: Compounds of formula (I), particularly a compound of formula (Ia), are non-peptide TPO mimetics, useful in the treatment of thrombocytopenia.
    Type: Grant
    Filed: May 3, 2002
    Date of Patent: April 13, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Juan I. Luengo, Kevin J. Duffy, Antony N. Shaw